AmgenvsApyx Medical

AMGN and APYX stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$470.84

Value $254B

+1.03%
AMGN's page

APYX

Apyx Medical Corporation

$2.76

Value $115M

-1.74%
APYX's page

Amgen (AMGN) has a market value of $254B and Apyx Medical (APYX) $115M. Over the last year, with dividends, AMGN moved +43.7% and APYX -29.2%. Dividend yield: AMGN 2.11%, APYX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$254B

    APYX$115M

    AMGN is 2,198 times APYX

  • Revenue, 12 months

    AMGN$38.9B

    APYX$60M

    AMGN is 653 times APYX

  • Net income, 12 months

    AMGN$9.4B

    APYX-$8.4M

  • Operating margin

    AMGN32.4%

    APYX-5.5%

    37.9 points apart

  • ROIC

    AMGN16.2%

    APYX-5.7%

    21.8 points apart

  • P/E

    AMGN27.0

    APYX–

  • Dividend yield

    AMGN2.1%

    APYX0.0%

    2.1 points apart

  • 5-year return

    AMGN+163.0%

    APYX-83.1%

    246.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+163.0%

APYX-83.1%

010020020222023202420252026
Returns by period
PeriodAMGNWith dividendsAPYXWith dividends
1 year since November 14, 2025+43.7%Price +39.8%-29.2%Price -29.2%
3 years since November 16, 2023+90.0%+23.9% a yearPrice +75.0%+32.1%+9.7% a yearPrice +32.1%
5 years since November 15, 2021+163.0%+21.3% a yearPrice +127.0%-83.1%-29.9% a yearPrice -83.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenAPYXApyx Medical

Valuation

AMGNAPYX
Valuation
Price$470.84$2.76
Market value$254B$115M
Enterprise value (EV)$295B–
P/E27.0–
P/E, 5-year median23.0–
P/B17.712.0
EV/EBIT23.4–
Free cash flow yield3.8%–

Results and growth

AMGNAPYX
Results and growth
Revenue, 12 months$38.9B$60M
Net income, 12 months$9.4B-$8.4M
Free cash flow, 12 months$9.6B-$8.9M
Earnings per share, 12 months$17.25-$0.19
Revenue growth, year on year10.0%9.9%
Revenue growth a year, past+7.6%over 5 years+13.8%over 5 years
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNAPYX
Margins and returns on capital
Gross margin70.9%63.4%
Operating margin32.4%-5.5%
Net margin24.1%-14.2%
ROIC16.2%-5.7%
ROE87.8%-78.8%

Balance sheet

AMGNAPYX
Balance sheet
Cash$13.2B$26M
Total debt$54.0B–
Net debt / EBITDA2.3–
Interest cover4.8×-0.6×

Dividends and buybacks

AMGNAPYX
Dividends and buybacks
Dividend yield2.1%–
Dividend per share, 12 months$9.94–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.1%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or APYX

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Apyx Medical?

By market value, Amgen ($254B) is about 2,197.9 times Apyx Medical ($115M), at today's prices.

How did AMGN and APYX stock do over the last 5 years?

Since November 15, 2021, AMGN's price moved +127.0% and APYX's -83.1%. With dividends: AMGN +163.0% (+21.3% a year), APYX -83.1% (-29.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or APYX?

The dividend yield at today's price is 2.11% for Amgen and none for Apyx Medical. Over the last twelve months they paid $9.94 and – per share.

Which has the higher profit margins, Amgen or Apyx Medical?

Over the last twelve months, the net margin was 24.1% for Amgen and -14.2% for Apyx Medical, and the operating margin 32.4% and -5.5%. Revenue was $38.9B and $60M.

Which is the better investment, Amgen or Apyx Medical?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.